Effect of the number of CMRFs involved in the development of MASLD on the prevalence of liver steatosis and the risk of advanced liver fibrosis [62] and the incident risk of CVD [63]
| Number of CMRFs | Prevalence of liver steatosis [62] | Prevalence of liver advanced fibrosis [62] | Incident risk of CVD, SHR (95% CI) [63] | P[63] |
|---|---|---|---|---|
| 0 | < 5% | 0% | 1.00 (reference) | |
| 1 | 36.0% (31.0%–41.4%) | 3.5% (0.2%–6.7%) | 1.41 (1.30–1.53) | < 0.001 |
| 2 | 53.7% (47.7%–59.6%) | 10.9% (6.2–15.6%) | 1.65 (1.53–1.79) | < 0.001 |
| 3 | 72.3% (65.3%–79.4%) | 14.5% (9.7%–19.2%) | 1.86 (1.72–2.02) | < 0.001 |
| 4 | 85.2% (81.8%–88.7%) | 21.7% (15.9%–27.4%) | 1.92 (1.76–2.09) | < 0.001 |
| 5 | 83.5% (79.8%–87.7%) | 24.2% (14.9%–33.5%) | 2.15 (1.95–2.37) | < 0.001 |
CMRFs: cardio-metabolic risk factors; CVD: cardio-vascular disease; MASLD: metabolic dysfunction-associated steatotic liver disease; SHR: subdistribution hazard ratio